Polares Medical’s EUR 46.3 million Series C is a clear bet on structural heart devices that can widen the treatable patient pool without forcing clinicians into an all-or-nothing choice between repair and full valve replacement.
The Swiss company said the round was oversubscribed and closed at USD 50 million (EUR 46.3 million). DC Global Ventures and Lumination Partners led the financing, with participation from existing investors and a new strategic investor. Terms beyond the headline amount were not disclosed.
Why this round matters
Mitral regurgitation remains one of the largest addressable segments in structural heart, but transcatheter solutions still face a trade-off: procedure complexity, anatomical constraints, and uncertainty around what options remain if the first intervention fails.
Polares is positioning MRace Posterior Leaflet Replacement between conventional mitral repair and total valve replacement. The device is designed to reinstate the activity of the posterior leaflet, one of the two key tissue structures that prevent blood backflow through the mitral valve.
The company’s framing aligns with a broader trend in cardiovascular medtech: device concepts that preserve future treatment pathways. MRace is designed as a transcatheter approach intended to expand treatment options across a broad spectrum of mitral anatomies, simplify the procedure, and keep subsequent interventions viable if needed.
Evidence base and clinical cadence
Polares said MRace has been implanted in more than 70 patients, with one-year data showing sustained safety and efficacy. The company also noted that clinical experience has validated the Posterior Leaflet Replacement concept and produced “compelling outcomes.”
Clinical studies are ongoing in the US, Europe, and Australia through the EXPLORE MR trial, with encouraging results reported.
For investors, that combination matters: early commercial logic (a differentiated procedural position) paired with growing clinical follow-through (multi-region studies and one-year data). It also helps explain why the Series C was oversubscribed.
Strategic angle: capital plus a strategic seat at the table
The syndicate includes a new strategic investor alongside financial backers. Polares did not name the strategic participant or outline any commercial or development collaboration.
That omission is material. In structural heart, strategic capital can unlock specific value drivers, but it can also introduce constraints.
Key questions include:
- Commercial pathway: whether Polares intends to build a direct commercial footprint, partner for distribution, or pursue a staged approach by geography.
- Manufacturing and quality systems: how the company plans to scale supply and compliance as trial volumes increase.
- Clinical and physician adoption: how reproducible the procedure is across centers and operators, and whether simplification claims translate into lower learning curves.
- Strategic alignment: whether the strategic investor’s interests point toward co-development, exclusive rights, or a future M&A option.
An investor involved in the round, Min Cui, said Polares is “addressing one of structural heart’s largest and most important markets with a differentiated approach.” The differentiation claim will ultimately be tested on two fronts: durability of outcomes and the breadth of anatomies that can be treated consistently.
What to watch next
- EXPLORE MR trial updates in the US, Europe, and Australia, including longer follow-up and procedural reproducibility across sites.
- Disclosure on the new strategic investor and any attached commercial, development, or governance rights.
- Regulatory sequencing: which geography becomes the initial launch market, and what evidence package Polares targets for approvals.
- Operational scale-up: manufacturing readiness and quality system maturity as implant volumes rise.
- Competitive positioning: how MRace’s “between repair and replacement” stance holds up as other transcatheter mitral solutions advance.